Gastroenteritis  >>  Ozespa (briakinumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ozespa (briakinumab) / AbbVie
NCT00562887 / 2008-004919-36: Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease

Terminated
2b
246
US, Canada, Europe, RoW
Placebo, ABT-874
Abbott
Crohn's Disease
04/10
 

Download Options